NagaChalasaniMD

PubMed

• Social determinants of health impact mortality from HCC and cholangiocarcinoma: a population-based cohort study.
  Lauren D Nephew, Dipika Gupta, Allie Carter, Archita P Desai, Marwan Ghabril, Kavish R Patidar, Eric Orman, Alisha Dziarski, Naga Chalasani> ;Hepatology Communications. 2023 Mar 1
• The impact of patient age and corticosteroids in patients with Sulfonamide hepatotoxicity.
  Robert J Fontana, David E Kleiner, Naga Chalasani, Herbert Bonkovsky, Jiezhun Gu, Huiman Barnhart, Yi-Ju Li, Jay H Hoofnagle> ;The American Journal of Gastroenterology. 2023 Feb 27
• Burden of fatty liver and hepatic fibrosis in persons with HIV: A diverse cross-sectional US multicenter study.
  Samer Gawrieh, Jordan E Lake, Paula Debroy, Julia A Sjoquist, Montreca Robison, Mark Tann, Fatih Akisik, Surya S Bhamidipalli, Chandan K Saha, Kimon Zachary, Gregory K...> ;Hepatology. 2023 Feb 22
• Machine learning liver histology scores correlate with portal hypertension assessments in nonalcoholic steatohepatitis cirrhosis.
  Mazen Noureddin, Zachary Goodman, Dean Tai, Elaine L K Chng, Yayun Ren, Pol Boudes, Harold Shlevin, Guadalupe Garcia-Tsao, Stephen A Harrison, Naga P Chalasani> ;Alimentary Pharmacology & Therapeutics. 2023 Feb 1
• Non-alcoholic fatty liver disease is not associated with impairment in health-related quality of life in virally suppressed persons with human immune deficiency virus.
  Samer Gawrieh, Kathleen E Corey, Jordan E Lake, Niharika Samala, Archita P Desai, Paula Debroy, Julia A Sjoquist, Montreca Robison, Mark Tann, Fatih Akisik, Surya S Bh...> ;Plos One. 2023 Jan 1
• Confusion assessment method accurately screens for hepatic encephalopathy and predicts short-term mortality in hospitalized patients with cirrhosis.
  Archita P Desai, Devika Gandhi, Chenjia Xu, Marwan Ghabril, Lauren Nephew, Kavish R Patidar, Noll L Campbell, Naga Chalasani, Malaz Boustani, Eric S Orman> ;Metabolic Brain Disease. 2022 Dec 19
• Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease.
  Arun J Sanyal, Stephen A Williams, Joel E Lavine, Brent A Neuschwander-Tetri, Leigh Alexander, Rachel Ostroff, Hannah Biegel, Kris V Kowdley, Naga Chalasani, Srinivasa...> ;Journal of Hepatology. 2023 Apr 1
• Identification of Reduced ERAP2 Expression and a Novel HLA Allele as Components of a Risk Score for Susceptibility to Liver Injury Due to Amoxicillin-Clavulanate.
  Paola Nicoletti, Andrew Dellinger, Yi Ju Li, Huiman X Barnhart, Naga Chalasani, Robert J Fontana, Joseph A Odin, Jose Serrano, Andrew Stolz, Amy S Etheridge, Federico ...> ;Gastroenterology. 2023 Mar 1
• Promotion of diet-induced obesity and metabolic syndromes by BID is associated with gut microbiota.
  Shengmin Yan, Jun Zhou, Hao Zhang, Zhen Lin, Bilon Khambu, Gang Liu, Michelle Ma, Xiaoyun Chen, Naga Chalasani, Xiao-Ming Yin> ;Hepatology Communications. 2022 Dec 1
• The Protection Conferred by HSD17B13 rs72613567 on Hepatic Fibrosis Is Likely Mediated by Lowering Ballooning and Portal Inflammation.
  Eduardo Vilar-Gomez, Tiebing Liang, Katherine Yates, Laura Wilson, Rohit Loomba, Naga Chalasani> ;Clinical Gastroenterology and Hepatology. 2022 Nov 17
• 1 citations
  Clinical features, outcomes, and HLA risk factors associated with nitrofurantoin-induced liver injury.
  Naga Chalasani, Yi-Ju Li, Andrew Dellinger, Victor Navarro, Herbert Bonkovsky, Robert J Fontana, Jiezhun Gu, Huiman Barnhart, Elizabeth Phillips, Craig Lammert, Tae-Hw...> ;Journal of Hepatology. 2023 Feb 1
• 3 citations
  Neighborhood poverty is associated with failure to be waitlisted and death during liver transplantation evaluation.
  Kawthar A Mohamed, Marwan Ghabril, Archita Desai, Eric Orman, Kavish R Patidar, John Holden, Susan Rawl, Naga Chalasani, Chandra Shekhar Kubal, Lauren D Nephew> ;Liver Transplantation. 2022 Sep 1
• Measuring Medication Use, Obstacles, and Knowledge in Individuals With Cirrhosis.
  Archita P Desai, Shahd Duzdar, Timothy Stump, Eric S Orman, Lauren Nephew, Kavish R Patidar, Marwan S Ghabril, Geoffrey Block, Michael Fallon, Naga Chalasani, Patrick ...> ;Clinical Gastroenterology and Hepatology. 2022 Aug 31
• 5 citations
  Unexplained liver test elevations after SARS-CoV-2 vaccination.
  John Guardiola, Craig Lammert, Evgenia Teal, Naga Chalasani> ;Journal of Hepatology. 2022 Jul 1
• Large Hepatic Adenomas and Hepatic Adenomatosis: A Multicenter Study of Risk Factors, Interventions, and Complications.
  Craig Lammert, Emily Toal, Karan Mathur, Vandana Khungar, Michael House, Lewis R Roberts, K Rajender Reddy, Naga Chalasani> ;The American Journal of Gastroenterology. 2022 Jul 1
• Letter: non-invasive prediction models to exclude cirrhosis in NAFLD-not everyone fits the mould. Authors' reply.
  Danielle Brandman, Marie Boyle, Stuart McPherson, Mark L Van Natta, Arun J Sanyal, Kris Kowdley, Brent Neuschwander-Tetri, Naga Chalasani, Manal F Abdelmalek, Norah A ...> ;Alimentary Pharmacology & Therapeutics. 2022 Jul 1
• 3 citations
  Acute kidney disease is common and associated with poor outcomes in patients with cirrhosis and acute kidney injury.
  Kavish R Patidar, Mobasshir A Naved, Ananth Grama, Mohammad Adibuzzaman, Arzina Aziz Ali, James E Slaven, Archita P Desai, Marwan S Ghabril, Lauren Nephew, Naga Chalas...> ;Journal of Hepatology. 2022 Jul 1
• 2 citations
  Leflunomide-induced liver injury: Differences in characteristics and outcomes in Indian and US registries.
  Harshad Devarbhavi, Marwan Ghabril, Huiman Barnhart, Mallikarjun Patil, Sujata Raj, Jiezhun Gu, Naga Chalasani, Herbert L Bonkovsky> ;Liver International. 2022 Jun 1
• A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological v...
  Marijana Vujkovic, Shweta Ramdas, Kim M Lorenz, Xiuqing Guo, Rebecca Darlay, Heather J Cordell, Jing He, Yevgeniy Gindin, Chuhan Chung, Robert P Myers, Carolin V Schne...> ;Nature Genetics. 2022 Jun 1
• 5 citations
  Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (NAFLD).
  Danielle Brandman, Marie Boyle, Stuart McPherson, Mark L Van Natta, Arun J Sanyal, Kris Kowdley, Brent Neuschwander-Tetri, Naga Chalasani, Manal F Abdelmalek, Norah A ...> ;Alimentary Pharmacology & Therapeutics. 2022 Jun 1
• Palliative Care, Patient-Reported Measures, and Outcomes in Hospitalized Patients With Cirrhosis.
  Eric S Orman, Andrew Yousef, Chenjia Xu, Hani Shamseddeen, Amy W Johnson, Lauren Nephew, Marwan Ghabril, Archita P Desai, Kavish R Patidar, Naga Chalasani> ;Journal of Pain and Symptom Management. 2022 Jun 1
• Corrigendum to: 'A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers' [J Hepatol 2022 (76) 275-282].
  John B Whitfield, Tae-Hwi Schwantes-An, Rebecca Darlay, Guruprasad P Aithal, Stephen R Atkinson, Ramon Bataller, Greg Botwin, Naga P Chalasani, Heather J Cordell, Ann ...> ;Journal of Hepatology. 2022 May 1
• Attitudes of Chinese Patients with Non-alcoholic Fatty Liver Disease Toward Participation in Clinical Trials from a National Multicenter Survey.
  Rui Huang, Huiying Rao, Fangfang Lv, Yuemin Nan, Wanhua Ren, Yan Huang, Jun Li, Hong Tang, Yuan Huang, Naga Chalasani, Lai Wei> ;Therapeutic Innovation & Regulatory Science. 2022 May 1
• 3 citations
  Removal of medicaid restrictions were associated with increased hepatitis C virus treatment rates, but disparities persist.
  Lauren D Nephew, Yumin Wang, Kawthar Mohamed, Deborah Nichols, Susan M Rawl, Eric Orman, Archita P Desai, Kavish R Patidar, Marwan Ghabril, Naga Chalasani, Monica L Ka...> ;Journal of Viral Hepatitis. 2022 May 1
• 4 citations
  Development of Alcohol-Associated Hepatitis Is Associated With Specific Changes in Gut-Modified Bile Acids.
  Mark D Muthiah, Ekaterina Smirnova, Puneet Puri, Naga Chalasani, Vijay H Shah, Calvin Kiani, Stephanie Taylor, Faridoddin Mirshahi, Arun J Sanyal> ;Hepatology Communications. 2022 May 1
• Join now to see all

Journal Articles

• In a Pilot Study, Reduced Fatty Acid Desaturase 1 Function Was Associated with Nonalcoholic Fatty Liver Disease and Response to Treatment in Children  
  Jingmei Lin, Naga P Chalasani, Nature
• Liver Stiffness Measurements in Patients with Non‐Cirrhotic Portal Hypertension – the Devil Is in the Details  
  Niharika Samala, Raj Vuppalanchi, Naga Chalasani, Hepatology
• Common Variation near IRF6 Is Associated with IFN-Β-induced Liver Injury in Multiple Sclerosis  
  Joshua C Denny, Zongqi Xia, Naga Chalasani, Nature
• Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the drug induced liver injury network  
  Hayashi PH, Barnhart HX, Fontana RJ, Chalasani N, Davern TJ, Talwalkar JA, Reddy KR, Stolz AA, Hoofnagle JC, Rockey DC, Liver Int, 1/24/2014
• Relationship between changes in serum keratin 18 fragments and changes in liver histology in adults and in children with nonalcoholic fatty liver disease  
  Vuppalanchi R, Jain AK, Deppe R, Yates K, Comerford M, Yates K, Masuoka HC, Neuschander-Tetri B, Loomba R, Brunt EM, Kleiner DE, Molleston JP, Schwimmer J, Lavine JE, ..., Clin Gastroenterol Hepatol, 1/17/2014
• Drug induced liver injury due to statins: experience of the US Drug Induced Liver Injury Network  
  Russo MW, Hoofnagle JH, Gu J, Fontana RJ, Barnhart H, Kleiner DE, Chalasani N, Bonkovsky HL, Hepatology, 1/2/2014
• Trials and tribulations in drug development for nonalcoholic steatohepatitis (Editoria)  
  Sanyal AJ, Chalasani N, Clinical Gastroenterology and Hepatology, 1/1/2014
• HIV-coinfection profoundly alters intrahepatic chemokine but not inflammatory cytokine profiles in HCV-infected subjects  
  Hu S, Ghabril M, Amet T, Hu N, Dyrd D, Vuppalanchi R, Saxena R, Desaif M, Johnson R, Gupta S, Chalasani N, Yu Q, PLoS, 1/1/2014
• Serum hepcidin levels are associated with obesity but not liver disease  
  Vuppalanchi R, Troutt JS, Konrad RJ, Ghabril M, Saxena R, Bell LN, Kowdley KV, Chalasani N, Obesity, 1/1/2014
• Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations  
  Kleiner DE, Chalasani N, Lee W, Fontana R, Bonkovsky HL, Watkins PB, Hayashi P, Davern T, Navarro V, Reddy KR, et al, Hepatology, 1/1/2014
• Management of dyslipidemia as a cardiovascular risk factor in individuals with nonalcoholic fatty liver disease  
  Corey KE, Chalasani N, Clinical Gastroenterology and Hepatology, 1/1/2014
• There is substantial morbidity and mortality associated with idiosyncratic drug induced liver injury: results from the DILIN prospective study  
  Fontana RJ, Hayashi PH, Gu J, Reddy KR, Barnhart H, Watkins PB, Serrano J, Lee WM, Chalasani N, Stolz A, Davern T, Talwalkar JA, Gastroenterology, 1/1/2014
• IL-12/Th1 and IL-23/Th17 biliiary microenvironment in primary biliary cirrhosis: Implications for therapy  
  Yang CY, Ma X, Tsuneyama K, Takahashi T, Chalasani N, Yang GX, Leung PSC, Ansari AA, Wu L, Strauss R, Gershwin ME, Hepatology, 1/1/2014
• Genetic polymorphism of cytochrome P450 4F2, vitamin E and histological response in adults and children with nonalcoholic fatty liver disease who participated in PIVEN...  
  Athinarayan S, Wei R, Bai S, Traber MG, Yates K, Cummings OW, Molleston JP, Liu W, Chalasani N, PLoS ONE, 1/1/2014
• Endoscopic therapy with 2-octyl-cyanoacrylate for the treatment of gastric varices  
  Kahloon A, Chalasani N, Dewitt J, Liangpunsakul S, Vinayek R, Ghabril M, Chiorean M, Digestive Diseases and Sciences, 1/1/2014
• Nodular regenerative hyperplasia due to trastuzumab emtansine  
  Force J, Saxena R, Schneider B, Storniolo AM, Sledge GW, Chalasani N, Vuppalanchi R, J Clinical Oncology, 1/1/2014
• An integrated omics analysis of human liver tissue revealed a mechanistic pathway underlying the role of FADS1 in hepatic lipid accumulation  
  Wang L, Athinarayanan S, Chalasani N, Zhang M, Liu W, Hepatology, 1/1/2014
• Genetic control of hepatic PNPLA3 transcription and a high-risk haplotype identifies a modifier allele for 148M and a high risk haplotype supporting the gain-of-functi...  
  Liu W, Anstee QM, Wang X, Gamazon ER, Athinarayanan S, Liu YL, Darlay R, Cordell HJ, the FLIP investigators, Daly AK, Day CP, Chalasani N, Gastroenterology, 1/1/2014
• Serum metabolic signatures of primary biliary cirrhosis and primary sclerosing cholangitis  
  Bell LN, Comerford M, Vuppalanchi R, Chalasani N, Liver International, 1/1/2014
• Clinical and histopathologic features of azithromycin-induced liver injury  
  Martinez M, Vuppalanchi R, Fontana R, Stolz A, Kleiner DE, Watkins PB, Barnhart H, Hoofnagle J, Chalasani N, Clinical Gastroenterology and Hepatology, 1/1/2014
• Obeticholic acid for nonalcoholic steatohepatitis: a randomized, placebo-controlled trial  
  Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek M, Chalasani N, Dasarathy S, e t al, New Engl J Med, 1/1/2014
• Drug Induced Liver Injury  
  Chalasani N & Hayashi PH (Co-editors), Seminars Liver Disease, 1/1/2014
• Drug-induced hepatic steatosis  
  Amacher DE, Chalasani N, Semin Liver Dis, 1/1/2014
• An assessment of statin liver safety - 2014 update  
  Bays H, Cohen DE, Chalasani NP, Harrison SA, J Clin Lipidol, 1/1/2014
• The diagnosis and Management of idiosyncratic drug induced liver injury: Practice guideline by the American College of Gastroenterology  
  Chalasani N, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, Fontana RJ on behalf of the American College of Gastroenterology, Am J Gastroenterology, 1/1/2014
• Join now to see all

Books/Book Chapters

• Drug Induced Liver Disease. 
  Vuppalanchi R, Chalasani NEditors: Kaplowitz N, DeLeve L.Marcel Dekker PublicationsEdition 3rd,2012
• Drug Induced Liver Injury: Epidemiology in the Western Countries. 
  Bell LN, Chalasani N2009
• Hepatology: A Textbook of Liver Disease. 
  Chapter: The Liver in Systemic Disease. 
  Chalasani N, Cummings OWEditors: Zakim D, Boyer TD.WB Saunders, Philadelphia, PAEdition 4th,2002
• Drug Induced Liver Disease. 
  Chapter: Hepatotoxicity due to cardiovascular and endocrinological drugs. 
  Bhardwaj S, Chalasani NEditors: Kaplowitz N, DeLeve L.Marcel Dekker Publications
• Evidence based Gastroenterology and Hepatology. 
  Chapter: Drug Induced Liver Injury. 
  Polson J, Chalasani NEditors: Younossi Z.Oxford PublicationsEdition 1st,
• Practical Gastroenterology and Hepatology. 
  Chapter: Drug Induced Liver Injury. 
  Bjornsson E, Chalasani NEditors: Talley N (Leader Editor), Lindor K and Vargas H.
• In Cecil's Text Book of Medicine. 
  Chapter: Alcoholic liver disease & Nonalcoholic fatty liver disease. 
  Chalasani NEditors: Ausiello & Goldman.Edition 23rd,
• Join now to see all

Abstracts/Posters

• Automatic quantification of liver histology in NAFLD. A promising tool to facilitate better histological characterization.
  Vanderbeck S, Bockhorst J, Komorowski R, Kleiner DE, Chalasani NP, Gawrieh S, Gastroenterology, DDW, 1/1/2014
• Little evidence for serious outcome in patients with chronic liver disease receiving potentially hepatotoxic drugs.
  Bjornsson E, Einarsdottir R, Jacobsen E, Chalasani NP, Gastroenterology, DDW, 1/1/2014
• Idiosyncratic drug induced liver injury in the United States: a report of 1257 prospectively enrolled patients.
  Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, et al, American College of Gastroenterology 2014 Annual Meeting, 1/1/2014
• Drug induced liver injury (DILI) in patients with underlying liver disease has worse prognosis: results from the drug induced liver injury network (DILIN) prospective ...
  Chalasani N, Bonkovsky HL, Fontana RJ, Gu J, Hayashi P, et al, AASLD Annual Meeting, 1/1/2014
• A comprehensive assessment of environmental exposures among 1000 North American primary sclerosing cholangitis patients with and without inflammatory bowel disease.
  Eaton JE, Juran BD, Atkinson EJ, Schlicht EM, Xie X, Andrade M, Luketic VA, Odin J, Koteish AA, Kowdley KV, Chopra KB, Hirshfield GM, Chalasani NP, Lazaridis LN, AASLD, 1/1/2014
• Disturbed sleep in highly prevalent in patients with cirrhosis and is independently associated with poor quality of life.
  Jackson M, Orman ES, Vuppalanchi R, Chalasani N, Ghabril M, AASLD Annual Meeting, 1/1/2014
• Global serum metabolomic profiling identifies a distinct metabolomic signature in patients with cirrhosis who have altered sleep pattern.
  Ghabril M, Jackson M, Bell LN, Gunst PR, Ornam ES, Vuppalanchi R, Chalasani N, AASLD Annual Meeting, 1/1/2014
• Delirium is related to hepatic encephalopathy and is associated with poor outcomes in cirrhosis.
  Orman ES, Perkins A, Ghabril M, Khan BA, Chalasani N, Boustani MA, AASLD annual meeting, 1/1/2014
• Clinical characteristics and outcomes of acute alcoholic hepatitis - preliminary report from the Translation al Research and Evolving Alcoholic Hepatitis Treatment (TR...
  Liangpunsakul S, Shah V, Sanyal A, Katz B, Kamath P, Saberi B, Ren Z, Puri P, Chalasani N, Crabb DW, Radaeva S, AASLD annual meeting, 1/1/2014
• Do liver transplant centers need different bench marks for quality metrics for managing hospitalized patients with cirrhosis.
  Ghabril M, Kwo PY, Tector J, Agrawal S, Chalasani N, AASLD annual meeting, 1/1/2014
• Fibroblast growth factor 21 treatment improves atherogenic diet-induced liver injury and metabolic syndrome in Ossabaw miniature swine.
  Gawrieh S, Alloosh M, Sheridan R, Liang T, Masuoka MC, Chalasani N, Sturek M, AASLD annual meeting, 1/1/2014
• Autoimmune hepatitis with inflammatory bowel disease in distinct and may be more refractory to traditional treatment.
  Bailey B, Fischer M, Vuppalanchi R, Ghabril M, Gawrieh M, Orman ES, Chalasani N, Lammert C, ACG annual meeting, 1/1/2014
• Biochemical response is associated with improved survival in patients with autoimmune hepatitis and advanced disease.
  Baily B, Orman ES, Vuppalanchi R, Ghabril M, Gawrieh S, Chalasani N, Lammert C, AASLD annual meeting, 1/1/2014
• Urea cycle disorders in patients with cirrhosis and hepatic encephalopathy.
  Ghabril M, Gotur R, Weber R, Hainline B, Chalasani N, AASLD annual meeting, 1/1/2014
• Early phase 1 results of GR-MD-02, a galectin-3 inhibitor, in patients with NASH and advanced fibrosis.
  Harrison SA, Chalasani N, Lawitz E, Noureddin M, Sanyal A, Schiano T, Siddique M, Tetri B, Traber PG, AASLD annual meeting, 1/1/2014
• NASH resolution is associated with improvements in HDL and triglyceride levels but not improvement in LDL or non-HDL-C levels.
  Corey KE, Vuppalanchi R, Wilson L, Cummings OW, Chalasani N, for the NASH CRN, AASLD Annual Meeting, 1/1/2014
• Profiles of serum microRNAs in acute drug-induced liver injury and their prognostic significance.
  Russo MW, Norton JB, Anderson W, Steurwald M, Barnhart H, Chalasani N, Fontana R, Hayashi P, Serrano J, Bonkosky HL, AASLD Annual Meeting, 1/1/2014
• Examination of dietary factors in autoimmune hepatitis utilizing social media and crowdsourcing.
  Comerford M, Chalasani N, Lammert C, AASLD Annual Meeting, 1/1/2014
• Portal vein thrombosis is a risk factor for early mortality and graft loss post liver transplantation: analysis of the UNOS database.
  Ghabril M, Kwo PY, Tector J, Lacerda M, Chalasani N, Agrawal S, AASLD Annual Meeting, 1/1/2014
• Cholestatic drug reactions are more likely to cause persistent liver injury and impaired quality of life during prolonged follow-up: results from the DILIN Prospective...
  Fontana RJ, Hayashi P, Reddy KR, Kleiner DE, Philips T, Barnhart H, Talwalkar J, Chalasani N, Lee W, Stolz A, Davern T, Watkins PB, Serrano J, Hoofnagle JH, AASLD Annual Meeting, 1/1/2014
• Genetic polymorphism of cytochrome P450 4F2 (CYP4F2) and histological response to vitamin E treatment in children and adults with nonalcoholic fatty liver disease.
  Dutta A, Chalasani N, DDW, 1/1/2013
• Changes in serum cytokeratin 18 levels significantly predict changes in liver histology in adults with nonalcoholic steatohepatitis.
  Vuppalanchi R, Deppe R, Yates K, Comerford M, Masuoka H, Tetri B, Loomba R, Brunt E, Kleiner D, Tonascia J, Chalasani N for the NASH CRN, DDW, 1/1/2013
• Novel genetic loci associated with steatohepatitis and fibrosis in Hispanic boys with nonalcoholic fatty liver disease.
  Lavine JE, Chalasani NP, Guo X, Kwon S, Schwimmer J, Molleston JP, Loomba R, Brunt EM, Chen IYD, Goodarzi M, Taylor KD, Yates KP, Unalp-Arida A, Rotter JI, DDW, 1/1/2013
• Mapping expression quantitative traits loci (eQTL) for PNPLA3gene identifies additional SNPs associated nonalcoholic fatty liver disease independent of rs738409.
  Wang X, Onjiko R, Anstee QM, Ratziu V, Liu YL, Cordell HJ, Darlay R, Day CP, Daly AK, Chalasani N, Liu W, EASL meeting, 1/1/2013
• Serum keratin fragment 18 (CK18) levels significantly predict changes in liver histology in children and adolescents with nonalcoholic fatty liver disease (NAFLD): Res...
  Jain AK, Deppe RB, Yates KP, Comerford M, Masuoka HC, Molleston JP, Schwimmer JB, Lavine JE, Brunt EM, Tonascia J, Kleiner DE, Chalasani NP, AASLD, 1/1/2013
• Join now to see all

Lectures

• Advances in Non-Alcoholic Fatty Liver Disease (NAFLD) 
  AGC 2018 Annual Scientific Meeting, Philadelphia, PA - 10/8/2018
• Initial Work-Up and Evaluation of a Patient With NAFLD 
  AGC 2018 Annual Scientific Meeting, Philadelphia, PA - 10/8/2018
• Vitamin D deficiency in Chronic Liver Disease. 
  1/1/2012
• Single Topic Symposium on Nonalcoholic Fatty Liver Disease. 
  Kolkata, India - 1/1/2012
• Nonalcoholic Fatty Liver Disease. 
  1/1/2011
• Vitamin E in NAFLD symposium. 
  Bethesda, MD - 1/1/2011
• Genetic basis of drug induced liver injury. 
  1/1/2011
• Annual Liver Course. 
  Charleston, SC - 1/1/2009
• Drug induced liver injury - Standardization of nomenclature and causality. 
  1/1/2008
• Using controlled clinical trials to learn more about acute drug-induced liver injury. 
  1/1/2008
• Drug Hepatotoxicity. 
  1/1/2007
• AGA-Duke GI series. 
  1/1/2007
• Annual Texas Hepatology Update . 
  San Antonio, TX, 2006, 2007 - 1/1/2007
• Portal Hypertension. 
  Atlanta, GA - 1/1/2007
• Meet the GI Experts. 
  1/1/2007
• An overview of Chronic Liver Disease and Cirrhosis. 
  1/1/2006
• Academic Hepatology Workshop. 
  1/1/2006
• Steatohepatitis. 
  Atlanta, GA - 1/1/2006
• Statin Hepatotoxicity. 
  1/1/2005
• Statin Toxicity (Liver Safety Panel). 
  Washington, DC - 1/1/2005
• Primary Sclerosing Cholangitis. 
  Bethesda, MD - 1/1/2005
• Drug Induced Liver Injury. 
  Atlanta, GA - 1/1/2005
• Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. 
  Baveno, Italy - 1/1/2005
• Recommendations of liver expert panel. 
  Washington, DC - 1/1/2005
• Drug-induced liver injury: Summary of a single topic clinical research conference. 
  Atlanta, GA - 1/1/2005
• Join now to see all

Other

• NAFLD and it management. 
  Chalasani N (Series Ed), Clinical Liver Disease, an electronic publication of the AASLD
  1/1/2012